Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was $8.09 for the day, up 6.17% from the previous closing price of $7.62. In other words, the price has increased by $6.17 from its previous closing price. On the day, 2.36 million shares were traded. BCRX stock price reached its highest trading level at $8.13 during the session, while it also had its lowest trading level at $7.57.
Ratios:
Our analysis of BCRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.73 and its Current Ratio is at 2.78.
On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.
Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 13 ’24 when Hutson Nancy J sold 7,000 shares for $7.54 per share. The transaction valued at 52,780 led to the insider holds 86,638 shares of the business.
Hutson Nancy J bought 7,000 shares of BCRX for $52,584 on Dec 13 ’24. On Jun 24 ’24, another insider, McKee Amy E, who serves as the Director of the company, sold 8,600 shares for $6.32 each. As a result, the insider received 54,352 and left with 27,831 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1675705984 and an Enterprise Value of 2187827456. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06. Its current Enterprise Value per Revenue stands at 5.303 whereas that against EBITDA is -68.496.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.87, which has changed by 0.4377358 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $8.88, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is 6.04%, while the 200-Day Moving Average is calculated to be 13.27%.
Shares Statistics:
BCRX traded an average of 2.27M shares per day over the past three months and 2298860 shares per day over the past ten days. A total of 207.12M shares are outstanding, with a floating share count of 195.42M. Insiders hold about 5.66% of the company’s shares, while institutions hold 81.86% stake in the company. Shares short for BCRX as of 1736899200 were 17013131 with a Short Ratio of 7.50, compared to 1734048000 on 17286947. Therefore, it implies a Short% of Shares Outstanding of 17013131 and a Short% of Float of 8.28.
Earnings Estimates
The current rating of Biocryst Pharmaceuticals Inc (BCRX) is the result of assessments by 5.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.3 and -$0.4 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.06, with 6.0 analysts recommending between $0.11 and -$0.24.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $131.77M to a low estimate of $130.8M. As of the current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $93.4MFor the next quarter, 4 analysts are estimating revenue of $126.64M. There is a high estimate of $132.06M for the next quarter, whereas the lowest estimate is $121.67M.
A total of 4 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $450.94M, while the lowest revenue estimate was $449.98M, resulting in an average revenue estimate of $450.36M. In the same quarter a year ago, actual revenue was $331.41MBased on 9 analysts’ estimates, the company’s revenue will be $548.9M in the next fiscal year. The high estimate is $557.68M and the low estimate is $538M.
